RealWorld Dynamix™: DMT New Starts in MS US 2018 Spotlight
Insights into the why… and the why not… behind first-line DMT brand selections for newly diagnosed multiple sclerosis patients. Using Biogen’s Tecfidera as an example, we delved into our recent RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis audit (n=274 neurologists, n=1,033 patients) to not only understand what drives Tecfidera’s selection as a popular first-line choice but to go deeper and reveal where and why Tecfidera is losing new start multiple sclerosis patients to the competition. See complimentary highlights from this study below.
Contact [email protected] for more information about the highlighted report or to see if your company has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.